Inbio Ventures
Inbio Ventures is a management company for Pharmstandard International (Luxembourg), a private venture capital fund, fully committed by the #1 pharmaceutical company in Russia, PJSC Pharmstandard (LSE: PHST).
We are the ambitious team of professionals with comprehensive experience in academic and biopharmaceutical industry, drug discovery and development, venture investments. We are supported by the Advisory Board of internationally recognized KOLs in various therapeutic areas. We are dedicated to investing in breakthrough drug development projects worldwide.
Due to our strategic alignments with the Generium/Pharmstandard group of companies we can offer to our partners much more than purely financial investors do – we position ourselves not only as a VC investor, but also as a strategic/co-development partner all the way from early-stage R&D to market access.
Sector
15 past transactions
Allena Pharmaceuticals
Series C in 2015
Allena Pharmaceuticals is developing and commercializing non-systemic protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrology and urologic conditions. Its proprietary technological approach enables the design, formulation, and delivery of non-absorbed and stable enzymes orally and in sufficient doses for activity in the GI tract.
It was founded in 2011 and headquartered in Newton, Massachusetts.
Avelas Biosciences
Series C in 2016
Avelas BioSciences, Inc. is a clinical stage biotechnology company that focuses on developing technologies that advance care for cancer surgery and therapeutic intervention. It develops AVB-620, an intravenously administered in vivo fluorescent protease-activatable peptide that detects, marks, and diagnoses cancer. The company was incorporated in 2008 and is based in La Jolla, California.
enGene
Series B in 2015
enGene is a developer of a mucosal immunotherapy platform designed to treat inflammatory bowel disease and diabetes. The company's mucosal immunotherapy platform has developed a flexible nucleotide delivery technology targeting mucosal tissues to treat numerous prevalent, chronic diseases via the induction or suppression of protein expression levels, enabling physicians and doctors to regenerate physiologic, meal-regulated insulin secretion from the gut of subjects with diabetes.
Jounce Therapeutics, Inc.
Series B in 2015
Jounce Therapeutics is dedicated to transforming the treatment of cancer. The company is discovering and developing first-in-class cancer immunotherapies designed to harness the immune system to seek out and attack cancerous cells and tumors. Jounce’s proprietary product engine is driving this transformational approach, which has the potential to drive
significantly more durable responses to treatment, extending and improving patients’ quality of life. Founded by world leaders in immunobiology, cancer biology and clinical and translational medicine, Jounce Therapeutics was launched in 2013 with funding from leading life sciences investor, Third Rock Ventures.
Neon Therapeutics
Series B in 2017
Neon Therapeutics is a clinical-stage biopharmaceutical company. It is focused in the field of neoantigen-targeted therapies, dedicated to transforming the treatment of cancer by directing the immune system towards neoantigens. The company's pipeline products are NEO-PV-01, NEO-PTC-01, and NEO-SV-01.
Protagonist Pty Ltd
Series B in 2013
Protagonist Pty Ltd. develops novel therapeutics for inflammatory and metabolic conditions. The company also involves in the discovery of peptide and small molecule compounds that mimic or inhibit therapeutically-relevant protein-protein interactions. In addition, it focuses on the discovery of drug candidates for targets previously resistant to small molecule discovery (protein-protein interactions), and on designing and constructing arrays of molecules that sample biologically-relevant regions of chemical diversity. Protagonist Pty Ltd was formerly known as Cytokine Mimetics Pty Ltd. The company was founded in 2001 and is based in Brisbane, Australia. Protagonist Pty Ltd operates as a subsidiary of Protagonist Therapeutics, Inc.
Argos Therapeutics, Inc.
Post in 2016
Argos Therapeutics, Inc., a biotechnology company, engages in developing immunotherapy treatments for cancer, infectious and autoimmune diseases, and transplantation rejection. The company has clinical trial programs in cancer and human immunodeficiency virus. Its products include AGS-0031 for metastatic renal cell carcinoma; AGS-0041 for HIV; CD83 soluble protein for transplant rejection/autoimmune disorders; Anti IFN-alpha monoclonal antibody2 for lupus; and regulatory T cell therapy3 for autoimmune disorders. The company was formerly known as MERIX Bioscience, Inc. Argos Therapeutics was founded in 1997 and is based in Durham, North Carolina.
TransMedics Group, Inc.
Private Equity Round in 2016
TransMedics, Inc. operates as a medical technology company. It offers organ care system, a multi-organ preservation technology that mirrors human physiology, minimizes ischemia, and provides the ability to optimize the organ during transport. The company is headquartered in Andover, Massachusetts.
Protagonist Pty Ltd
Series C in 2015
Protagonist Pty Ltd. develops novel therapeutics for inflammatory and metabolic conditions. The company also involves in the discovery of peptide and small molecule compounds that mimic or inhibit therapeutically-relevant protein-protein interactions. In addition, it focuses on the discovery of drug candidates for targets previously resistant to small molecule discovery (protein-protein interactions), and on designing and constructing arrays of molecules that sample biologically-relevant regions of chemical diversity. Protagonist Pty Ltd was formerly known as Cytokine Mimetics Pty Ltd. The company was founded in 2001 and is based in Brisbane, Australia. Protagonist Pty Ltd operates as a subsidiary of Protagonist Therapeutics, Inc.
Neon Therapeutics
Series B in 2017
Neon Therapeutics is a clinical-stage biopharmaceutical company. It is focused in the field of neoantigen-targeted therapies, dedicated to transforming the treatment of cancer by directing the immune system towards neoantigens. The company's pipeline products are NEO-PV-01, NEO-PTC-01, and NEO-SV-01.
Allena Pharmaceuticals
Series B in 2014
Allena Pharmaceuticals is developing and commercializing non-systemic protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrology and urologic conditions. Its proprietary technological approach enables the design, formulation, and delivery of non-absorbed and stable enzymes orally and in sufficient doses for activity in the GI tract.
It was founded in 2011 and headquartered in Newton, Massachusetts.
Aquinox Pharmaceuticals
Series C in 2013
Aquinox Pharmaceuticals Inc., a pharmaceutical company, engages in discovery, development, and commercialization of small molecule therapeutics for the treatment of cancer and inflammatory disease. It offers AQX-MN100, a drug used to treat cancer and inflammatory disease, as well as SH2-containing inositol 5'-phosphatase inhibition program for blood cell recovery. The company was founded in 2004 and is based in Vancouver, Canada.
TransMedics Group, Inc.
Series F in 2016
TransMedics, Inc. operates as a medical technology company. It offers organ care system, a multi-organ preservation technology that mirrors human physiology, minimizes ischemia, and provides the ability to optimize the organ during transport. The company is headquartered in Andover, Massachusetts.
Proteon Therapeutics
Series D in 2014
Proteon Therapeutics, Inc is a biopharmaceutical company developing pharmaceuticals to address the medical needs of patients with renal and vascular diseases.
The company leverages a unique understanding of tissue remodeling to develop a pipeline of proprietary therapeutics.
Proteon Therapeutics’ first drug candidate (PRT-201) is in development for the improvement of blood flow following vascular surgery procedures.
The company’s initial clinical focus is vascular access for hemodialysis and peripheral arterial disease (PAD).
Argos Therapeutics, Inc.
Series E in 2013
Argos Therapeutics, Inc., a biotechnology company, engages in developing immunotherapy treatments for cancer, infectious and autoimmune diseases, and transplantation rejection. The company has clinical trial programs in cancer and human immunodeficiency virus. Its products include AGS-0031 for metastatic renal cell carcinoma; AGS-0041 for HIV; CD83 soluble protein for transplant rejection/autoimmune disorders; Anti IFN-alpha monoclonal antibody2 for lupus; and regulatory T cell therapy3 for autoimmune disorders. The company was formerly known as MERIX Bioscience, Inc. Argos Therapeutics was founded in 1997 and is based in Durham, North Carolina.